Matrix Metalloproteinase 9 Exerts Antiviral Activity against Respiratory Syncytial Virus.
Increased lung levels of matrix metalloproteinase 9 (MMP9) are frequently observed during respiratory syncytial virus (RSV) infection and elevated MMP9 concentrations are associated with severe disease. However little is known of the functional role of MMP9 during lung infection with RSV. To determine whether MMP9 exerted direct antiviral potential, active MMP9 was incubated with RSV, which showed that MMP9 directly prevented RSV infectivity to airway epithelial cells. Using knockout mice the effect of the loss of Mmp9 expression was examined during RSV infection to demonstrate MMP9's role in viral clearance and disease progression. Seven days following RSV infection, Mmp9-/- mice displayed substantial weight loss, increased RSV-induced airway hyperresponsiveness (AHR) and reduced clearance of RSV from the lungs compared to wild type mice. Although total bronchoalveolar lavage fluid (BALF) cell counts were similar in both groups, neutrophil recruitment to the lungs during RSV infection was significantly reduced in Mmp9-/- mice. Reduced neutrophil recruitment coincided with diminished RANTES, IL-1β, SCF, G-CSF expression and p38 phosphorylation. Induction of p38 signaling was required for RANTES and G-CSF expression during RSV infection in airway epithelial cells. Therefore, MMP9 in RSV lung infection significantly enhances neutrophil recruitment, cytokine production and viral clearance while reducing AHR.
Mount Sinai St. Luke's Medical Center, Mount Sinai Health System, Division of Pulmonary, Critical Care and Sleep Medicine, New York, NY, United States of America.
Abdoulaye J
AJ
Dabo
Mount Sinai St. Luke's Medical Center, Mount Sinai Health System, Division of Pulmonary, Critical Care and Sleep Medicine, New York, NY, United States of America.
Neville
N
Cummins
Mount Sinai St. Luke's Medical Center, Mount Sinai Health System, Division of Pulmonary, Critical Care and Sleep Medicine, New York, NY, United States of America.
Edward
E
Eden
Mount Sinai St. Luke's Medical Center, Mount Sinai Health System, Division of Pulmonary, Critical Care and Sleep Medicine, New York, NY, United States of America.
Patrick
P
Geraghty
D000818:Animals; D017209:Apoptosis; D016535:Bronchial Hyperreactivity / Q000276:immunology / Q000821:virology*; D002478:Cells, Cultured; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D006801:Humans; D020780:Matrix Metalloproteinase 9 / Q000502:physiology*; D051379:Mice; D008807:Mice, Inbred BALB C; D018345:Mice, Knockout; D020556:Neutrophil Infiltration; D012130:Respiratory Hypersensitivity / Q000139:chemically induced / Q000276:immunology / Q000821:virology; D018357:Respiratory Syncytial Virus Infections / Q000201:enzymology* / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D018113:Respiratory Syncytial Virus, Human / Q000472:pathogenicity*
D016207:Cytokines; D020780:Matrix Metalloproteinase 9; C501830:Mmp9 protein, mouse